Biocon Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 353.2, up 3.52% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 25209.65. The Sensex is at 82725.53, up 0.41%. Biocon Ltd has added around 7.63% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 4.53% in last one month and is currently quoting at 21948, up 0.51% on the day. The volume in the stock stood at 47.75 lakh shares today, compared to the daily average of 26.07 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 354.1, up 3.46% on the day. Biocon Ltd is up 4.22% in last one year as compared to a 8.09% gain in NIFTY and a 11.76% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge).

The said approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities.

Siddharth Mittal, chief executive officer and managing director, Biocon, said: ?The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon?s mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India.?

Biocon is an innovation-led global biopharmaceutical company focused on improving affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe

The company?s consolidated net profit surged 154.2% to Rs 344.50 crore on 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24.

The counter shed 0.45% to end at Rs 334.05 on the BSE.

Powered by Capital Market - Live News

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1.3% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25003.4. The Sensex is at 82230.01, down 0.12%. Biocon Ltd has added around 3.59% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 2.33% in last one month and is currently quoting at 21633.2, up 1% on the day. The volume in the stock stood at 7.5 lakh shares today, compared to the daily average of 36.71 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 344.85, up 1.2% on the day. Biocon Ltd is up 11.77% in last one year as compared to a 10.98% gain in NIFTY and a 13.77% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Biocon announced that the Board of Directors of the Company at its meeting held on 8 May 2025, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News